1. Lalonde R.L. et al Model?based drug development. Clin. Pharmacol. Ther. 82, 21?32 (2007). [PubMed]

2. EFPIA MID3 Workgroup et al Good practices in model?informed drug discovery and development (MID3): practice, application and documentation. CPT Pharmacometrics Syst. Pharmacol. 5, 93?122 (2016). [PubMed]

3. Huang S.M., Abernethy D.R., Wang Y., Zhao P. & Zineh I. The utility of modeling and simulation in drug development and regulatory review. J. Pharm. Sci. 102, 2912?2923 (2013). [PubMed]

4. Manolis E., Rohou S., Hemmings R., Salmonson T., Karlsson M. & Milligan P.A. The role of modeling and simulation in development and registration of medicinal products: output from the EFPIA/EMA Modeling and Simulation Workshop. CPT Pharmacometrics Syst. Pharmacol. 2, e31 (2013). [PubMed]

5. Wagner C. et al Application of physiologically based pharmacokinetic (PBPK) modeling to support dose selection: report of an FDA Public Workshop on PBPK. CPT Pharmacometrics Syst. Pharmacol. 4, 226?230 (2015). [PubMed]

6. Shepard T., Scott G., Cole S., Nordmark A., & Bouzom F. Physiologically based models in regulatory submissions: output from the ABPI/MHRA forum on physiologically based modeling and simulation. CPT Pharmacometrics Syst. Pharmacol. 4, 221?225 (2015). [PubMed]

7. European Medicines Agency Committee for Medicinal Products for Human Use: DRAFT, Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modeling and simulation. EMA/CHMP/458101/2016. <http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500211315.pdf> (2016).

8. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER): DRAFT GUIDANCE, Physiologically Based Pharmacokinetic Analyses?Format and Content Guidance for Industry. <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM531207.pdf> (2016).



% 9. Zhao P. Application of Physiologically?based Pharmacokinetic Modeling to Support Dosing Recommendations ? The US Food and Drug Administration Experience. EMA Workshop on qualification and reporting of physiologically?based pharmacokinetic (PBPK) modelling and simulation. <http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2016/12/WC500217569.pdf> (2016). [PMC free article] [PubMed]



10. Nagai N. Role of Pharmacometrics in Drug Development and Regulatory Review: PMDA perspectives. PMDA?Keio Joint Symposium on Pharmacometrics. <https://www.pmda.go.jp/files/000209059.pdf> (2015).









@Manual{R-base,
  title = {R: A Language and Environment for Statistical Computing},
  author = {{R Core Team}},
  organization = {R Foundation for Statistical Computing},
  address = {Vienna, Austria},
  year = {2017},
  url = {https://www.R-project.org/},
}
@Manual{extrapol,
  title = {Reflection paper on extrapolation of efficacy and safety in paediatric medicine development},
  author = {{EMEA}},
  organization = {EMEA},
  address = {Vienna, Austria},
  year = {2016},
  url = {http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/04/WC500204187.pdf},
}
@Manual{fda2a,
  title = {Guidance for Industry End-of-Phase 2A Meetings},
  author = {{FDA}},
  organization = {U.S. Department of Health and Human Services Food and Drug Administration},
  address = {Maryland, US},
  year = {2009},
  url = {https://www.fda.gov/downloads/Drugs/.../Guidances/ucm079690.pdf},
}
@Manual{generalclinpharm,
  title = {Guidance for Industry: General Clinical Pharmacology Considerations for Pediatric Studies for Drugs and Biological Products},
  author = {{FDA}},
  organization = {U.S. Department of Health and Human Services Food and Drug Administration},
  address = {Maryland, US},
  year = {2014},
}
@Manual{pbpk,
  title = {Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation},
  author = {{EMEA}},
  organization = {EMEA},
  address = {Vienna, Austria},
  year = {2016},
  url = {http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500211315.pdf},
}
@Manual{E4,
  title = {International Conference on Harmonisation (ICH) guidance: E4 Dose-Response Information to Support Drug Registration},
  author = {{ICH}},
  organization = {International Conference on Harmonisation},
  address = {Vienna, Austria},
  year = {1994},
}
@Manual{E7,
  title = {International Conference on Harmonisation (ICH) guidance: E7 Studies in Support of Special Populations: Geriatrics},
  author = {{ICH}},
  organization = {International Conference on Harmonisation},
  address = {Vienna, Austria},
  year = {1993},
}
@Manual{kfda,
  title = {의약품 개발 시 집단 약동학 활용을 위한 가이드라인},
  author = {{의약품심사부 종양약품과}},
  organization = {식품의약품안전평가원},
  year = {2015},
  address = {대한민국},
  url = {https://www.nifds.go.kr/brd/m_15/view.do?seq=7038},
}
@Manual{drug-label,
  title = {Mechanistic Oral Absorption Modeling and Simulation for Formulation Development and Bioequivalence Evaluation; Public Workshop},
  author = {Liang Zhao}, 
  organization = {U.S. Department of Health and Human Services Food and Drug Administration},
  year = {2016},
  url = {https://www.fda.gov/downloads/Drugs/NewsEvents/UCM505000.pdf},
}
